a:head bio AG secures additional private funding to advance its human brain tissue platform
a:head bio AG concluded a 7-digit funding round to drive the expansion of its disease model development and platform automation. The funding round was primarily backed by existing shareholders, with two new investors joining in 2025.
This investment will empower a:head to extend into a variety of indications with a strong focus on neurodegenerative diseases. The company also plans to increase the range of tissue types and create more sophisticated human brain models to enhance clinical relevance. "This funding underscores investor confidence in our technology and strategic direction," says a:head bio AG CEO Oliver Szolar. "We are focused on expanding disease model capabilities and sophistication to deliver greater value." “We are excited to fuel our efforts in automating our human brain organoid platform,” says Josh Bagley, CSO of a:head. “This investment will support our goal of being able to produce and screen organoids with high quality at scale.”
Contact
a:head bio AG, Dr.-Bohr-Gasse 7, VBC6, 1030 Vienna, Austria
Oliver Szolar, CEO
oliver.szolar@aheadbio.com
+43 1 3660519
www.aheadbio.com